Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
7.9.2023 10:00:00 EEST | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.
Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.
CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.
CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.
Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.”
Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: “ We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.
We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.
Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.
For more information visit www.cerbaresearch.com
About CIRION
CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).
Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907759314/en/
Contact information
Press contacts:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com
CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 16:30:00 EET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
Andersen Consulting Expands Capabilities with Assure Consulting24.2.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its platform with addition of collaborating firm Assure Consulting, a Germany-based management consulting firm specializing in project management and project portfolio management. Founded in 2003, Assure Consulting supports organizations in successfully delivering complex projects and transformations. The firm helps clients establish and operate Project Management Offices (PMOs), strengthen governance and portfolio management, and apply classical, agile, or hybrid project management approaches tailored to their needs. Assure Consulting also provides hands-on support for large-scale system and process rollouts, integrated change management for organizational and cultural transformation, and coaching and training programs aligned with internationally recognized project management standards to build sustainable capabilities within client organizations. “This collaboration allows us to scale our project-delivery expertise and agile transformation capabilitie
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 16:00:00 EET | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom